Loading…
← CockpitCompetitor Analysis › 002349.SZ Jinghua Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Jinghua Pharmaceutical Group Co., Ltd. Class A002349.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 75
Mkt cap
$785M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$25.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.7 pp
WACC 5.3%
Hurdle
-5 pp
Req g minus delivered
Close · CNYCN¥6.64
1D-1.5%
1W-6.0%
1M-14.1%
3M-6.2%
6M-7.7%
YTD-8.5%
1Y-13.1%
ATR %4.1%
52w lowhigh30.8% off high

What Jinghua Pharmaceutical does

Employees: 1,462

Jinghua Pharmaceutical at a glance

Size Jinghua Pharmaceutical (002349.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $785M, the 2628th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.64 on 18 Nov 2026.

Performance Over six months the shares fell 7.7%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +7.3%); the operating margin is 19.9% (peer median 8.9%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 2.5× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.7 points above its cost of capital (5.3% WACC).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 97002349.SZ 93
Six months, rebased to 100: Jinghua Pharmaceutical against the median of its 20 peers (local-currency closes).

Jinghua Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.48BCN¥1.45BCN¥1.39BCN¥1.50BCN¥1.56B
Revenue growth—+4%-7%-4%—
Gross profitCN¥814MCN¥726MCN¥665MCN¥702MCN¥681M
EBITDAn/aCN¥347MCN¥300MCN¥372MCN¥323M
Net incomeCN¥233MCN¥219MCN¥213MCN¥248MCN¥212M
Free cash flowCN¥270MCN¥326MCN¥290MCN¥270MCN¥305M
Capital expenditureCN¥30.4MCN¥20.3MCN¥30.9MCN¥28.4MCN¥61.6M
Total debtCN¥13.9MCN¥77.3MCN¥35.0MCN¥36.0MCN¥39.2M

Quarterly statements and history in the cockpit →

Jinghua Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%ARDX000411IRWDBLISSGVSGUDORICSANOFI002390RIGL688073SUVENLXRX30010024240029072171002349.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jinghua Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×250×500×750×ARDX000411IRWDGUDSANOFI002390SUVENLXRX0024242171002349.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jinghua Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%BLISSGVSGUDSANOFI002390RIGL6880733001COLL6078002424002907002349.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jinghua Pharmaceutical is the large dot.

Jinghua Pharmaceutical competitors and peer comparison

How Jinghua Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jinghua Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002349.SZPeer medianRank in peer set
1-month return-14.1%-0.9%5th lowest of 19
6-month return-7.7%-4.7%8th lowest of 19
Distance from 52-week high-30.8%-32.8%8th highest of 19
Revenue growth (TTM)+1.9%+7.3%7th lowest of 19
Operating margin19.9%8.9%4th highest of 19
EV / Sales3.1×2.5×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)-2.5%6.6%3rd least demanding of 12
Growth delivered (Del g)+2.6%+10.1%6th lowest of 12
Hurdle (Req g minus delivered)-5.1 pp-3.1 pp6th least demanding of 12
ROIC minus cost of capital+4.7 pp-0.0 pp6th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a

Questions

Which companies are Jinghua Pharmaceutical's closest peers?
The cockpit's peer set: Ardelyx (ARDX), Zhejiang Int'l (000411.SZ), Sichuan Neautus Traditional Chinese (2206.HK), Bambusa Therapeutics (BBTX), Ironwood Pharmaceuticals (IRWD), Bliss GVS Pharma (BLISSGVS.NS), Knight Therapeutics (GUD.TO), Oric Pharmaceuticals (ORIC).
Is Jinghua Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 2.5×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Jinghua Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -7.7% against -4.7% for the median peer; over one year -13.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.